A 68-year-old with COPD exacerbation receives albuterol 5 mg nebulizer every 2 hours, with persistent mild wheeze but new tremor, HR 128 and potassium 3.1, and the nurse asks about the next aerosol. History includes frequent ectopy on telemetry. Which aerosol drug adjustment best balances continued bronchodilation with systemic beta-agonist toxicity?

Switching to albuterol by MDI with spacer every 4 hours lowers systemic beta-agonist exposure while preserving bronchodilation: an MDI with spacer can achieve similar airway deposition at a lower nominal dose than a 5 mg nebulizer, and the longer interval allows tremor, tachycardia, potassium shift, and ectopy risk to improve while treating persistent mild wheeze. Monitoring heart rate helps guide further care. Adding ipratropium while continuing albuterol 5 mg nebulizers every 2 hours can support bronchodilation in COPD exacerbation, but it does not offset the frequent high-dose beta-agonist stimulation driving HR 128, potassium 3.1, and excitability with frequent ectopy. Switching to levalbuterol at the same frequent nebulized interval may be better tolerated by some patients, but unchanged dose frequency and nebulized load can still produce dose-dependent systemic effects. Holding all inhaled bronchodilators until values and symptoms normalize appropriately recognizes toxicity but leaves ongoing obstruction untreated and risks worsening. Exam caveat: persistent mild wheeze calls for continued, safer bronchodilation—not escalation or cessation—when systemic toxicity is explicit. Practical check: reassess wheeze, work of breathing, oximetry, heart rate and rhythm, tremor, and potassium; verify spacer technique, and add non-beta-agonist maintenance per protocol if wheeze persists.